Literature DB >> 20006606

VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop.

Oscar Gonzalez-Moreno1, Jon Lecanda, Jeffrey E Green, Victor Segura, Raul Catena, Diego Serrano, Alfonso Calvo.   

Abstract

Vascular endothelial growth factor (VEGF) is overexpressed during the transition from prostate intraepithelial neoplasia (PIN) to invasive carcinoma. We have mimicked such a process in vitro using the PIN-like C3(1)/Tag-derived Pr-111 cell line, which expresses low levels of VEGF and exhibits very low tumorigenicity in vivo. Elevated expression of VEGF164 in Pr-111 cells led to a significant increase in tumorigenicity, invasiveness, proliferation rates and angiogenesis. Moreover, VEGF164 induced strong changes in cell morphology and cell transcriptome through an autocrine mechanism, with changes in TGF-beta1- and cytoskeleton-related pathways, among others. Further analysis of VEGF-overexpressing Pr-111 cells or following exogenous addition of recombinant VEGF shows acquisition of epithelial-mesenchymal transition (EMT) features, with an increased expression of mesenchymal markers, such as N-cadherin, Snail1, Snail2 (Slug) and vimentin, and a decrease in E-cadherin. Administration of VEGF led to changes in TGF-beta1 signaling, including reduction of Smad7 (TGF-beta inhibitory Smad), increase in TGF-betaR-II, and translocation of phospho-Smad3 to the nucleus. Our results suggest that increased expression of VEGF in malignant cells during the transition from PIN to invasive carcinoma leads to EMT through an autocrine loop, which would promote tumor cell invasion and motility. Therapeutic blockade of VEGF/TGF-beta1 in PIN lesions might impair not only tumor angiogenesis, but also the early dissemination of malignant cells outside the epithelial layer. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20006606     DOI: 10.1016/j.yexcr.2009.11.020

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  53 in total

1.  Regulation of adhesion by vascular endothelial growth factor in HaCaT cells.

Authors:  Chunming Li; Xiaoyong Man; Wei Li; Jiong Zhou; Jiaqi Chen; Suiqing Cai; Min Zheng
Journal:  Mol Cell Biochem       Date:  2010-09-28       Impact factor: 3.396

Review 2.  The roles of HLH transcription factors in epithelial mesenchymal transition and multiple molecular mechanisms.

Authors:  Yue Teng; Xu Li
Journal:  Clin Exp Metastasis       Date:  2013-10-26       Impact factor: 5.150

Review 3.  Epithelial-to-mesenchymal transitions and circulating tumor cells.

Authors:  Arnaud Bonnomet; Anne Brysse; Anthony Tachsidis; Mark Waltham; Erik W Thompson; Myriam Polette; Christine Gilles
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-05-07       Impact factor: 2.673

4.  The CCL2/CCR2 axis enhances IL-6-induced epithelial-mesenchymal transition by cooperatively activating STAT3-Twist signaling.

Authors:  Wei Chen; Qiang Gao; Siqi Han; Fei Pan; Wei Fan
Journal:  Tumour Biol       Date:  2014-10-16

5.  Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature.

Authors:  Jonah R Riddell; Wiam Bshara; Michael T Moser; Joseph A Spernyak; Barbara A Foster; Sandra O Gollnick
Journal:  Cancer Res       Date:  2011-02-22       Impact factor: 12.701

Review 6.  The P2X7 Receptor in the Maintenance of Cancer Stem Cells, Chemoresistance and Metastasis.

Authors:  Vanessa Fernandes Arnaud-Sampaio; Izadora Lorrany Alves Rabelo; Henning Ulrich; Claudiana Lameu
Journal:  Stem Cell Rev Rep       Date:  2020-04       Impact factor: 5.739

7.  Epithelial-mesenchymal transition in cancer: Role of the IL-8/IL-8R axis.

Authors:  Zhiwei Zhao; Shichao Wang; Yingbo Lin; Yali Miao; Ye Zeng; Yongmei Nie; Peng Guo; Guangyao Jiang; Jiang Wu
Journal:  Oncol Lett       Date:  2017-04-13       Impact factor: 2.967

Review 8.  The network of epithelial-mesenchymal transition: potential new targets for tumor resistance.

Authors:  Danupon Nantajit; Dong Lin; Jian Jian Li
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-01       Impact factor: 4.553

Review 9.  Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?

Authors:  Katrien De Bock; Massimiliano Mazzone; Peter Carmeliet
Journal:  Nat Rev Clin Oncol       Date:  2011-05-31       Impact factor: 66.675

10.  DDB2 suppresses epithelial-to-mesenchymal transition in colon cancer.

Authors:  Nilotpal Roy; Prashant V Bommi; Uppoor G Bhat; Shaumick Bhattacharjee; Indira Elangovan; Jing Li; Krushna C Patra; Dragana Kopanja; Adam Blunier; Richard Benya; Srilata Bagchi; Pradip Raychaudhuri
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.